These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 16098611

  • 1. The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses.
    Crouch CF, Daly J, Henley W, Hannant D, Wilkins J, Francis MJ.
    Vet Immunol Immunopathol; 2005 Dec 15; 108(3-4):345-55. PubMed ID: 16098611
    [Abstract] [Full Text] [Related]

  • 2. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an 'American lineage' H3N8 virus.
    Crouch CF, Daly J, Hannant D, Wilkins J, Francis MJ.
    Vaccine; 2004 Dec 02; 23(3):418-25. PubMed ID: 15530689
    [Abstract] [Full Text] [Related]

  • 3. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.
    Paillot R, Grimmett H, Elton D, Daly JM.
    Vet Res; 2008 Dec 02; 39(3):21. PubMed ID: 18252187
    [Abstract] [Full Text] [Related]

  • 4. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP.
    Vaccine; 2006 Feb 20; 24(8):1180-90. PubMed ID: 16194586
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.
    Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, Sindle T, Jessett D, Black L, Bublot M, Pardo MC, Audonnet JC.
    Am J Vet Res; 2007 Feb 20; 68(2):213-9. PubMed ID: 17269889
    [Abstract] [Full Text] [Related]

  • 6. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.
    Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM.
    Vet Immunol Immunopathol; 2006 Aug 15; 112(3-4):225-33. PubMed ID: 16621023
    [Abstract] [Full Text] [Related]

  • 7. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
    Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ.
    Vaccine; 2009 Sep 04; 27(40):5530-7. PubMed ID: 19607950
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of a whole inactivated EI vaccine against a recent EIV outbreak isolate and comparative detection of virus shedding.
    Paillot R, Prowse L, Donald C, Medcalf E, Montesso F, Bryant N, Watson J, Jeggo M, Elton D, Newton R, Trail P, Barnes H.
    Vet Immunol Immunopathol; 2010 Aug 15; 136(3-4):272-83. PubMed ID: 20400185
    [Abstract] [Full Text] [Related]

  • 9. Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination.
    Soboll G, Hussey SB, Minke JM, Landolt GA, Hunter JS, Jagannatha S, Lunn DP.
    Vet Immunol Immunopathol; 2010 May 15; 135(1-2):100-107. PubMed ID: 20018384
    [Abstract] [Full Text] [Related]

  • 10. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse.
    Paillot R, Prowse L.
    Vet Immunol Immunopathol; 2012 Jan 15; 145(1-2):516-21. PubMed ID: 22178272
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine.
    Lopez AM, Hecker R, Mutwiri G, van Drunen Littel-van den Hurk S, Babiuk LA, Townsend HG.
    Vet Immunol Immunopathol; 2006 Nov 15; 114(1-2):103-10. PubMed ID: 16950519
    [Abstract] [Full Text] [Related]

  • 15. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
    Van de Walle GR, May MA, Peters ST, Metzger SM, Rosas CT, Osterrieder N.
    Vaccine; 2010 Jan 22; 28(4):1048-55. PubMed ID: 19897066
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.
    Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J.
    Vet Microbiol; 2013 Mar 23; 162(2-4):396-407. PubMed ID: 23146168
    [Abstract] [Full Text] [Related]

  • 18. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza.
    Tabynov K, Kydyrbayev Zh, Ryskeldinova Sh, Assanzhanova N, Sansyzbay A.
    Vaccine; 2014 May 23; 32(25):2965-71. PubMed ID: 24726250
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings--a randomised blind study.
    Gildea S, Arkins S, Walsh C, Cullinane A.
    Vaccine; 2011 Nov 15; 29(49):9214-23. PubMed ID: 21983355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.